The most commonly reported adverse effects are gastrointestinal in nature and include: Nausea (particularly during dose escalation) Vomiting Diarrhoea Constipation Decreased appetite These effects are generally dose-dependent and tend to be most pronounced during the initial weeks of treatment when the dose is being gradually increased
Constipation: On the flip side, some individuals may experience constipation while taking GLP-1 medications, particularly if they have a history of gastrointestinal issues or a low-fiber diet
The semaglutide vs retatrutide vs tirzepatide comparison covers the mechanistic differences in detail
Instead, it gently turns down the food noisea phrase thats used frequently to describe the effects of GLP-1sto make it easier to establish new habits
Weekly WeighIns and Ongoing Support Patients are monitored weekly so adjustments can be made quickly and safely
The results of the TRANSCEND-T2D-1 trial, published in March 2026, showed that participants with type 2 diabetes mellitus, who took retatrutide 12mg, lost an average of 16.8% of their body weight at 40 weeks